<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439125</url>
  </required_header>
  <id_info>
    <org_study_id>AMBS-ELTO-201</org_study_id>
    <nct_id>NCT02439125</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients</brief_title>
  <official_title>Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amarantus BioScience Holdings, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amarantus BioScience Holdings, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of eltoprazine
      to treat levodopa-induced dyskinesia in patients with Parkinson's disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled, crossover, dose-range finding study in patients with
      Parkinson's disease and levodopa-induced dyskinesia. The study will examine the effects of
      three different doses of eltoprazine HCl, compared to placebo, on severity of dyskinesia,
      parkinsonian symptoms, patient function, safety and tolerability, using Parkinson's disease
      rating scales, patient diaries and physiological measurement of abnormal movement by means of
      motion sensors.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical impact of dyskinesia measured by total UDysRS (Unified Dyskinesia Rating Scale) score</measure>
    <time_frame>84 days</time_frame>
    <description>Clinical impact on dyskinesia measured by total UDysRS (Unified Dyskinesia Rating Scale) score at the end of each Treatment Period on Days 21, 42, 63 and 84</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• PD motor symptoms assessed by MDS-UPDRS, diaries and physiological measurement with motion sensor system</measure>
    <time_frame>84 days</time_frame>
    <description>• PD motor symptoms assessed by MDS-UPDRS, diaries and physiological measurement with motion sensor system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyskinesia severity using physiological motion sensor system</measure>
    <time_frame>84 days</time_frame>
    <description>Dyskinesia severity using physiological motion sensor system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient function using MDS-UPDRS and UDysRS questionnaires quantify dyskinesia and Parkinsonian motor symptoms.</measure>
    <time_frame>84 days</time_frame>
    <description>Patient function using MDS-UPDRS and UDysRS questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: adverse events, physical and neurological exams, safety laboratory values, vital signs and ECG</measure>
    <time_frame>94 days</time_frame>
    <description>Safety and tolerability: adverse events, physical and neurological exams, safety laboratory values, vital signs and ECG</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Dyskinesia</condition>
  <arm_group>
    <arm_group_label>Eltoprazine HCl 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eltoprazine HCl 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eltoprazine HCl 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules to be taken orally b.i.d. for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltoprazine HCl</intervention_name>
    <description>2.5 mg b.i.d. orally for 3 weeks</description>
    <arm_group_label>Eltoprazine HCl 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltoprazine HCl</intervention_name>
    <description>5.0 mg b.i.d. orally for 3 weeks</description>
    <arm_group_label>Eltoprazine HCl 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltoprazine HCl</intervention_name>
    <description>7.5 mg b.i.d. orally for 3 weeks</description>
    <arm_group_label>Eltoprazine HCl 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>b.i.d. orally for 3 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  outpatient with idiopathic PD

          -  stable dose of anti-parkinsonian medication for at least four weeks before the
             Screening Visit

          -  daily levodopa dose ≥300 mg per day divided into at least three doses

          -  treated with levodopa for at least three years prior to study entry

          -  moderate to severely disabling levodopa-induced dyskinesia for at least three months
             prior to study entry

          -  dyskinesia for, on average, &gt;25% of the waking day

        Exclusion Criteria:

          -  inability to use the motion sensors or electronic diaries correctly

          -  surgical treatment for PD, e.g. Deep Brain Stimulation, within the last six months or
             planned during the study

          -  unstable co-existing psychiatric disease including psychosis, depression or cognitive
             impairment

          -  Mini Mental State Examination score of &lt;24

          -  moderate or severe renal, or severe hepatic, impairment

          -  treatment with selective serotonin re-uptake inhibitors (SSRI) or any combined
             serotonin-norepinephrine re-uptake inhibitors (SNRI), such as tryptizol, citalopram,
             escitalopram, sertraline, mianserin, mirtazapin, paroxetin, venlafaxine and St John's
             Wort, within four weeks prior to the Screening Visit

          -  treatment with medications with the potential for drug-interactions (MAO-A inhibitors,
             apomorphine, aripiprazol, carbamazepine, clozapine, phenytoin, tramadol, quetiapine,
             varfaine, valproic acid). Patients taking amantadine will comprise no more than 25% of
             the study population

          -  current history of a clinically significant and uncontrolled medical condition that
             may affect the safety of the patient or preclude adequate participation in the study

          -  pregnant or breast-feeding

          -  received any other investigational medicinal product within 30 days of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Keywood, MBBS,MRCP,</last_name>
    <role>Study Director</role>
    <affiliation>Amarantus BioScience Holdings, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center, Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://foxtrialfinder.michaeljfox.org/</url>
  </link>
  <results_reference>
    <citation>Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.</citation>
    <PMID>25669730</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>levodopa</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>parkinsons disease</keyword>
  <keyword>PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Eltoprazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

